Allarity Therapeutics Receives Refusal to File Letters from U.S. FDA

 

• Refusal to File letters concern the new drug application for dovitinib and the DRP®-Dovitinib companion diagnostic pre-market approval application
  

• Allarity intends to seek guidance from the FDA on how to further advance dovitinib
  and its accompanying DRP®-Dovitinib companion diagnostic towards approval

https://finance.yahoo.com/news/allarity-therapeutics-receives-refusal-file-211500688.html